in Inner Mongolia Furui Technology Co., Ltd., formerly known as Inner Mongolia, Mongolian Furui Pharmaceutical Co., Ltd., on November 26, 1998 was established. The main shareholders are the crown of a chairman, China High-Tech Investment Group, Shenzhen Erdos Asset Management Limited and other companies and individuals. January 20, 2010, the company listed on the Shenzhen Stock Exchange GEM stock code 300 049, the existing registered capital of 96.2 million yuan.

companies adhere to the "professional services in the field of liver disease to liver fibrosis as the core" development strategy, efforts to establish a unique professional service system Ferrer. Since the establishment of the date that create value for social responsibility, through the joint efforts of all colleagues, raising the public awareness of the level of liver fibrosis for patients with advanced liver fibrosis and accurate diagnostic tools and effective liver fibrosis treatment, to bring health to patients with liver disease, on this basis reflects the company's existence and development value.

as a pioneer in the field of diagnosis and treatment of liver fibrosis, the company based on domestic and global perspective of the big vision to provide comprehensive professional diagnosis and treatment of liver fibrosis, has become the research, production, sales, network integration services for the modern pharmaceutical enterprise, with independent intellectual property rights of high-end core technology to provide the field of diagnosis and treatment of liver fibrosis solutions to provide effective treatment of liver fibrosis, liver fibrosis in the field of leading enterprises. Our main products Fufangbiejiarangan film in 1999 by the National Science and Technology Progress Award, 2001, Science and Technology Department of Inner Mongolia Autonomous Region as high-tech achievements, 2003 was approved by the State Food and Drug Administration to protect traditional Chinese medicine, is the national patent Office granted patent, has been listed since 1999 to maintain market share in the field of hepatic fibrosis the first place. To further improve the products and business structure, the company relies on its own R & D and innovation advantage, the initial formation of a service platform for online diagnosis of liver fibrosis, liver fibrosis established professional company's brand image, as the technology is improving, the business scale the gradual growth of the company's future lay the foundation for sustained and stable growth.

company in October 2000 by the State Food and Drug Administration's GMP certification to become autonomous through the first GMP certified pharmaceutical manufacturing company, in 2002 National Science and Technology identified as high-tech enterprises, Economic Commission of Inner Mongolia in 2008 received, the Joint Science and Technology Department of the seven bureaus of the regional technology center issued certification. The company now has more than 200 large and medium production equipment (sets), which can be tablets, capsules, ointment three categories of rubber production of the drug more than 50 varieties, reaching the advanced level of the pharmaceutical industry.

companies adhere to specialized academic promotion, marketing ideas, focusing on liver fibrosis in the field of academic high ground as the goal of academic brand building, with large domestic and foreign research institutions, well-known universities and enterprises cooperation, creating a powerful and efficient system of practical research in the field of diagnosis and treatment of liver disease continue to make breakthroughs, to form a unique core competencies. After years of unremitting efforts, the company has established a nationwide hospital and retail pharmacies as the main channel to promote the academic network, has a well-trained professional, standardized marketing team and a major provinces and cities across the country the efficient functioning of marketing system.

in the development of business, the company also bravely assumed social responsibility and actively participate in various public welfare, the company donated 50 million yuan, and China Foundation for Hepatitis Prevention and Control cooperate to establish "WANG Bao-en liver fibrosis research fund" in order to improve our level of liver fibrosis and liver disease quality of life, to promote the cause of China's further development of liver disease prevention and control.

to expand drug sales channels, so that people eat is safe and effective drugs at reasonable prices ease in 2001, the company of "benefiting the people, health promotions "business purposes, founded the Inner Mongolia Furui Pharmaceutical Co., Ltd., established in line with GSP standard warehouse, computer network management, logistics and distribution systems and quality inspection, testing centers and other facilities in 2002 through the National Food Drug Administration of the GSP certification, and formed a center of radiation for the Inner Mongolia autonomous national sales network. In July 2006, established the Beijing Saifulikang Network Technology Development Co., Ltd., established a "Chinese love liver net" for hospitals, doctors, patients build a trinity of health service platform, and provide for China's long-term liver disease financial assistance and education for liver disease.